BMRN vs MDGL: stock comparison and AI forecast
Biomarin Pharmaceutical Inc (BMRN) and Madrigal Pharmaceuticals, Inc. (MDGL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMRN Biomarin Pharmaceutical Inc
- Price
- $56.03 +3.5% · 6M
- Market Cap
- $10.85B
- P/E Ratio
- 560.3x
- Size
- large-cap
- AI Forecast
MDGL Madrigal Pharmaceuticals, Inc.
- Price
- $400.10 -25.2% · 6M
- Market Cap
- $9.24B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BMRN is 1.2 times larger than MDGL by market capitalization ($10.85B against $9.24B).
- Over the last six months BMRN returned +3.5% and MDGL -25.2%.
- MDGL carries 1.29 times debt per unit of equity, against 0.85 times for BMRN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMRN | MDGL |
|---|---|---|
| Market Cap | $10.85B | $9.24B |
| P/E Ratio | 560.31x | – |
| P/B Ratio | 1.73x | 14.74x |
| EPS | $0.10 | $-5.96 |
| Book Value/Share | $32.32 | $27.14 |
| Revenue/Share | $18.88 | $76.96 |
| FCF/Share | $2.88 | $-7.30 |
Profitability & Margins
| Metric | BMRN | MDGL |
|---|---|---|
| ROE | – | -24.8% |
| ROA | – | -10.8% |
| ROIC | 1.1% | -15.6% |
| Gross Margin | 76.0% | – |
| Operating Margin | 3.1% | -8.6% |
| Net Margin | – | -8.7% |
| EBT Margin | 1.2% | -7.9% |
| Tax Rate | 143.8% | – |
Financial Health
| Metric | BMRN | MDGL |
|---|---|---|
| Current Ratio | 2.44x | 3.05x |
| Quick Ratio | 1.32x | 2.78x |
| D/E Ratio | 0.85x | 1.29x |
| Financial Leverage | 1.85x | 2.29x |
| Interest Coverage | – | -24.1x |
| Working Capital | $2.32B | $933M |
Cash Flow
| Metric | BMRN | MDGL |
|---|---|---|
| Operating Cash Flow | $677M | -$157M |
| Free Cash Flow | $558M | -$169M |
| Capital Spending | -$119M | -$12M |
| OCF Growth YoY | -26.0% | – |
| FCF Growth YoY | -33.0% | – |
| FCF/Sales | 15.3% | -9.5% |
| CapEx/Sales | 3.2% | 0.7% |
Operational Efficiency
| Metric | BMRN | MDGL |
|---|---|---|
| Asset Turnover | 0.32x | 1.24x |
| Receivables Turnover | 3.4x | 7.8x |
| Inventory Turnover | 0.5x | – |
| Fixed Assets Turnover | 3.7x | 127.4x |
| Days Sales Outstanding | 107 days | 47 days |
| Days Inventory | 746 days | – |
| Payables Period | 54 days | – |
| Cash Conversion Cycle | 799 days | – |
Income Statement
| Metric | BMRN | MDGL |
|---|---|---|
| Total Revenue | $3.66B | $1.78B |
| Operating Income | $114M | -$153M |
| Net Income | – | -$155M |
| R&D Expense | $759M | $486M |
| SG&A Expense | $1.43B | $1.06B |
| Cost of Goods Sold | $879M | – |
Dividend & Shareholder Information
| Metric | BMRN | MDGL |
|---|---|---|
| Shares Outstanding | 194M | 23M |
| EPS Growth | -95.4% | – |
BMRN vs MDGL: stock comparison and AI forecast
Which is bigger, BMRN or MDGL?
BMRN is 1.2 times larger than MDGL by market capitalization ($10.85B against $9.24B).
Which stock performed better over the last six months, BMRN or MDGL?
Over the last six months BMRN returned +3.5% and MDGL -25.2%.
Which one does Intratio's AI model rank higher, BMRN or MDGL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.